These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28357969)

  • 1. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
    Tsai J; Thase ME; Mao Y; Ng-Mak D; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):236-245. PubMed ID: 28357969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis.
    Swann AC; Fava M; Tsai J; Mao Y; Pikalov A; Loebel A
    CNS Spectr; 2017 Apr; 22(2):228-235. PubMed ID: 28300012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
    McIntyre RS; Cucchiaro J; Pikalov A; Kroger H; Loebel A
    J Clin Psychiatry; 2015 Apr; 76(4):398-405. PubMed ID: 25844756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.
    Suppes T; Silva R; Cucchiaro J; Mao Y; Targum S; Streicher C; Pikalov A; Loebel A
    Am J Psychiatry; 2016 Apr; 173(4):400-7. PubMed ID: 26552942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension.
    Goldberg JF; Ng-Mak D; Siu C; Chuang CC; Rajagopalan K; Loebel A
    CNS Spectr; 2017 Apr; 22(2):220-227. PubMed ID: 28264739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial.
    Sramek J; Loebel A; Murphy M; Mao Y; Pikalov A; Cutler NR
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():12-17. PubMed ID: 28499900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial.
    Clayton AH; Tsai J; Mao Y; Pikalov A; Loebel A
    J Clin Psychiatry; 2018 Aug; 79(5):. PubMed ID: 30086213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
    Sajatovic M; Forester BP; Tsai J; Kroger H; Pikalov A; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2016 Oct; 77(10):e1324-e1331. PubMed ID: 27529375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale.
    Vöhringer PA; Sani G; Barroilhet SA; Mao Y; Ghaemi SN
    J Clin Psychopharmacol; 2020; 40(5):491-494. PubMed ID: 32701901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model.
    Goldberg JF; Siu C; Mao Y; Tsai J; Pikalov A; Calabrese JR; Loebel A
    J Affect Disord; 2020 Dec; 277():1045-1054. PubMed ID: 33065813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels.
    Montgomery SA; Altamura AC; Katila H; Datto C; Szamosi J; Eriksson H
    Int Clin Psychopharmacol; 2014 Mar; 29(2):93-105. PubMed ID: 24162081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Rickels K; Athanasiou M; Robinson DS; Gibertini M; Whalen H; Reed CR
    J Clin Psychiatry; 2009 Mar; 70(3):326-33. PubMed ID: 19284933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts.
    Suppes T; Kroger H; Pikalov A; Loebel A
    J Psychiatr Res; 2016 Jul; 78():86-93. PubMed ID: 27089521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.
    Nasrallah HA; Cucchiaro JB; Mao Y; Pikalov AA; Loebel AD
    CNS Spectr; 2015 Apr; 20(2):140-7. PubMed ID: 24955752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression.
    Kato T; Ishigooka J; Miyajima M; Watabe K; Fujimori T; Masuda T; Higuchi T; Vieta E
    Psychiatry Clin Neurosci; 2020 Dec; 74(12):635-644. PubMed ID: 32827348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
    Loebel A; Cucchiaro J; Silva R; Kroger H; Hsu J; Sarma K; Sachs G
    Am J Psychiatry; 2014 Feb; 171(2):160-8. PubMed ID: 24170180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.